radiotherapy to reduce local recurrence risk; however, external beam radiotherapy (EBRT) is inconvenient, comprising 3-7 weeks of daily treatments (Early Breast Cancer Trialists' Collaborative Group, 2005; Smith et al., 2011) . Patients must also consider the potential toxicities of radiotherapy, and sometimes decide to forego radiotherapy (increasing their risk of recurrence) or choose mastectomy to avoid radiotherapy side effects and inconveniences (Boscoe et al., 2011; Collins et al., 2009; NSW Department of Health, 2011; Pan, Smith, & Shih, 2014; Throckmorton & Esserman, 2009 ).
The introduction of partial breast irradiation now means that patients having breast conservation surgery may need to decide between two radiotherapy options, trading a possible increased risk of local recurrence for a shorter, and hence more convenient, radiotherapy treatment (Vaidya et al., 2014; Veronesi et al., 2010) .
Targeted intraoperative radiotherapy (TARGIT-IORT) delivers radiation directly to the primary tumour bed, during a single session at the time of wide local excision (WLE) or shortly afterwards. The TARGIT-A trial randomised women having breast conservation surgery to receive either standard EBRT or intraoperative radiotherapy (TARGIT-IORT). At 5 years after randomisation, more women in the TARGIT-IORT arm (2.1%) than the EBRT arm (1.1%) had experienced a local recurrence when IORT was delivered during WLE (before pathology results were available); this difference was not statistically significant and was within the 2.5% pre-specified non-inferiority margin. However, non-inferiority could not be established when IORT was delivered as a separate procedure, with local recurrence rates of 5.4% vs. 1.7% for post-pathology IORT and EBRT respectively. (Vaidya et al., 2014 (Vaidya et al., , 2015 . Patients treated with TARGIT-IORT overall had the same breast cancer mortality risk but significantly fewer non-breast cancer deaths than those treated with EBRT (1.4% vs. 3.5% p = 0.0086) (Vaidya et al., 2014) . This finding was supported by a recent meta-analysis of partial breast irradiation techniques vs.
whole breast radiotherapy (Vaidya et al., 2016) .
TARGIT-IORT has been shown to have less skin toxicity and better patient-reported outcome measures such as pain and cosmetic outcome when compared to EBRT (Keshtgar et al., 2013; Vaidya et al., 2010; Welzel et al., 2013) .
When the TARGIT-A study began recruiting, the risk of local recurrence following IORT was unknown, as was the level of risk that patients might accept in order to have the more convenient single treatment. We hypothesised that even if TARGIT-IORT treatment resulted in a higher risk of local recurrence, a proportion of patients may nevertheless be willing to trade a greater long-term local recurrence risk for increased short-term convenience. We also hypothesised that demographic and social factors including employment status, having dependents, and living further from a treatment centre may influence these patient preferences.
Trade-off methodology has been validated for determining patient preferences in oncology (Blinman, King, Norman, Viney, & Stockler, 2012; Blinman et al., 2010 Blinman et al., , 2011 Duric, Fallowfield et al., 2005; Stiggelbout & de Haes, 2001) . Respondents are instructed to consider the positive and negative effects of a treatment together with the probabilities of these effects (Duric & Stockler, 2001; Simes & Coates, 2001) . Subjects choose between competing treatment options with differing outcomes (in this case, differing risks of local recurrence), and thus, measure the relative desirability of one treatment option compared with another.
Successful recruitment to TARGIT-A demonstrated that treatment-naïve patients were willing to try a more convenient treatment option with an unknown level of risk. This sub-study was designed to investigate what maximum increase in risk of local recurrence patients would accept to receive TARGIT-IORT in place of EBRT, in order to subsequently contextualise the TARGIT-A clinical results from a patient perspective.
| PATIENTS AND ME THODS
A total of 3,451 patients from 33 centres in 11 countries were recruited into TARGIT-A between 2000 and 2012 (ISRCTN-34086741) (Vaidya et al., 2010 (Vaidya et al., , 2014 . Patients with early breast cancer suitable for breast-conserving surgery were randomized to receive either a single dose of TARGIT-IORT (50 kV X-rays with INTRABEAM(TM) Carl Zeiss, Oberkochen Germany) or conventional 3-7 weeks EBRT. TARGIT-IORT patients with high-risk pathology as previously described also received EBRT (15%) (Vaidya et al., 2010) .
Stage-1 of this patient preference study was prospectively planned as a sub-study of the TARGIT-A Trial. In 2011, treatment preferences were collected from 213 TARGIT-A patients treated at least 3 months previously as per their allocated randomisation.
Participants were reviewed by their Radiation Oncologist for suitability for inclusion in the preference sub-study. Patients were ineligible if the study would be considered an unwelcome imposition based on social, psychological or other circumstances ( Figure 1 ).
From 2012 to 2014 preferences were collected from a further 123 usual-care patients recently diagnosed with breast cancer but yet to receive radiotherapy (Stage-2). Stage-2 (pre-treatment group) was developed as a follow-up study to test additional hypotheses informed by Stage-1. In 2015, Stage-2 participants who had initially been surveyed pre-treatment, and who had not declined further contact, were mailed a second "post-treatment" questionnaire.
Human research ethics approvals were obtained for all studies and all participants provided written informed consent.
| Instruments and evaluations

| Stage-1, TARGIT-A group
TARGIT-A participants were mailed an invitation letter with an optout card. Patient preference, demographics and the Patient Disease And Treatment Assessment (Patient DATA) questionnaires utilised in previous preference studies were adapted for this study and were mailed to patients who did not opt out (Supporting Information Appendices S1-S3) (Blinman et al., 2010; Simes & Coates, 2001) . The questionnaire method of eliciting patient preferences has been validated through prospective comparison to scripted face-to-face methodology (Blinman et al., 2010) .
The preference questionnaire was used to determine the largest 5-years recurrence risk that women considered acceptable in return for the shorter duration and altered toxicity profile of TARGIT-IORT.
Participants were asked to imagine they knew what their risk of local recurrence would be with conventional EBRT. They were then asked to determine the maximum increased risk of local recurrence they would accept in order to receive TARGIT-IORT. Risk of recurrence of EBRT was represented as 3% in Question 1, 6% in Question 2, then as 3/100 in Question 3 and 6/100 in Question 4 (Supporting Information Appendix S1).
Acknowledging that an event such as treatment for breast cancer may alter some variable patient characteristics, such as work status, where appropriate the demographics questionnaire was answered for three separate time points: "before breast cancer," "during breast cancer treatment" and "now" (being the time of questionnaire completion) (Supporting Information Appendix S2).
The patient DATA form consists of 22 questions which are scored from 0 (no trouble at all) to 10 (Worst Imaginable) by participants to indicate the extent to which different aspects of their treatment troubled them. Participants were instructed to recall symptoms during radiotherapy treatment. The scores are grouped as shown in Supporting Information Appendix S3.
| Stage-2, pre-treatment group
Potential participants were identified during multidisciplinary team meetings, and the study was discussed by the attending surgeon.
Interested patients were telephoned by the study coordinator who then mailed out questionnaires to those who agreed to participate.
The preference questionnaire was modified slightly for the pretreatment setting (Supporting Information Appendix S4). Stage-1 participants had demonstrated a preference for risk presented as a proportion; hence, the questions represented as percentages were removed. This allowed an alternative preference scenario to be examined: TARGIT-IORT being delivered either during WLE, or as a second procedure. Demographics were also collected. Participants who agreed to further contact were mailed a second questionnaire 1 year later, to capture preferences "post-treatment."
IORT: intra-operative radiotherapy; EBRT: external beam radiotherapy; NESB: non-English speaking background. *Missing data: questionnaires were returned with key data missing, and attempts to contact patients to retrieve missing data were unsuccessful
| Analysis and interpretation
Statistical significance was set at p < 0.01 to account for multiple comparisons (Bland & Altman, 1995; Bottomley et al., 2004) . IBM-SPSS-V23 (SPSS Inc., Chicago, IL, USA) was used for all analyses. The Kappa statistic was used to determine reliability between percentage and proportion based questions and between the two baseline levels of recurrence risk presented.
Kappa scores were interpreted based on levels of agreement de- Almost perfect (Landis & Koch, 1977) . Non-parametric Wilcoxon Signed-Rank (paired) tests were used to test differences between responses for TARGIT-IORT as a separate procedure vs. TARGIT-IORT delivered during WLE, and between the pre-treatment vs.
post-treatment preference setting. Multivariate and univariate
Poisson regression was utilised to test potential predictors of patient preference.
| RE SULTS
A total of 336 consecutive TARGIT-A participants were reviewed for suitability, and exclusions are shown in Figure 1 . Two hundred and thirteen evaluable responses were received; 108 had received TARGIT-IORT, 101 had received EBRT and four had received both TARGIT-IORT and EBRT.
A total of 151 standard care patients were invited to participate in Stage-2 (pre-treatment preference study), with 123 evaluable questionnaires received. The "post-treatment" questionnaire was mailed to 119 of the 123 initial participants with 85 returned ( Figure 2 ).
Demographics were similar across all groups, although Stage-2 patients were slightly younger, had more child dependents, and higher levels of education and employment than Stage-1 participants (Table 1) . These factors were considered in single and multivariate analysis of patient preference (Supporting Information Appendix S5). Where stayed during surgery.
| Preference results
TA B L E 1 (Continued) respectively). Overall acceptance (those not selecting "never") of TARGIT-IORT was 98% for the Stage-1 post-TARGIT-IORT group, 58% for the Stage-1 post-EBRT group, 86% for the Stage-2 pretreatment group and 59% for the Stage-2 post-treatment group.
The only significant characteristic impacting preference in
Stage-1 was the treatment patients had received on the TARGIT-A Trial (TARGIT-IORT or EBRT; p = <0.001, mean difference 2.5). This remained unchanged when controlling for other potential drivers of treatment preference.
In the pre-treatment Stage-2 participants, no significant relationship was observed between preference outcomes and demographics. Post-treatment, having child dependents was a weak predictor for greater acceptance of TARGIT-IORT as a separate procedure (p = 0.006) in multivariate analysis, but this was not significant for IORT during WLE (p = 0.019). Stage-2 patients were more accepting of TARGIT-IORT pre-treatment than they were post-treatment (Wilcoxon signed-rank test p < 0.001).
| Analyses specific to the TARGIT-A group (Stage-1)
Twenty-six percentage of participants preferred risk represented as a percentage, 56% preferred a proportion out of 100% and 15% had no preference.
Multivariate and univariate analysis revealed no significant differences in patient characteristics over the different time points used in the demographics questionnaire ("before breast cancer," "during treatment" and "now"), hence only the "now" data were used in the final analysis. There was no difference in preferences when patients were presented with alternative scenarios of IORT as a separate procedure or during WLE at either level of baseline recurrence risk (Wilcoxon signed-rank test p = 0.338 and 0.335 respectively) for pre-treatment or post-treatment groups (p = 0.216 and 0.624 respectively).
| Analyses specific to the pre-treatment group (Stage 2)
Participants could opt to leave free text comments on the final page. This data are described in Supporting Information Appendix S7.
| D ISCUSS I ON AND CON CLUS I ON
Patient preference studies are increasingly recognised as an important secondary, and in some cases primary, outcome in health care research. This preference study utilised validated questionnaire methodology in two sequential studies, each with two patient cohorts; Stage-1 included patients who had already received either
TARGIT-IORT or EBRT on the TARGIT-A trial and Stage-2 included breast cancer patients yet to receive radiotherapy, most of whom were surveyed again post-treatment.
The most striking finding of this research was the discovery that preferences elicited in the post-treatment setting yield very different results to those elicited in the pre-treatment setting. This study, in which preferences were first elicited from patients who had completed treatment with one of two radiotherapy modalities to which they had been randomly assigned, demonstrated that the most important determinant of treatment preference was the treatment already experienced by that patient. Despite patients having entered the trial accepting a 50% chance of randomisation to either radiotherapy technique, those who had been randomised to TARGIT-IORT strongly favoured the treatment they had received, even at a hypothetical increased risk of recurrence compared to the EBRT group. Furthermore, 43% of patients who had been randomised to and received EBRT indicated they would not accept TARGIT-IORT at all. The only plausible explanation for this, in patients with similar characteristics who had provided informed consent to randomisation to either treatment, is that patients were justifying the treatment they had received, therefore indirectly justifying their decision to participate in the randomised trial, thus potentially avoiding decisional regret. Optional comments made by
Stage-1 participants demonstrated that as their experience with the treatment they had received on the randomised study was acceptable to them, they were biased towards that treatment when completing the preference questionnaire. There were very few comments suggesting that the recalled toxicities of treatment im- These preference results showed that around a third of patients were willing to accept TARGIT-IORT at a higher risk than that which was observed in the TARGIT-A trial, which found non-significant absolute increases in risk of recurrence of 1% in the group having IORT during WLE and 3.7% in the group having IORT as second separate procedure. Although IORT during WLE is the recommended approach, it is not always feasible. These results suggest that some women, at least before they have experienced treatment, may accept a risk of recurrence in keeping with the results of TARGIT-A in order to receive IORT as a separate procedure, if immediate IORT is not possible. The results of this study therefore provide a further discussion point for providers when considering obstacles to radiotherapy access, especially for patients in rural and remote areas.
If health professionals and informed patients accept the small additional risk of local recurrence for a more convenient treatment schedule, then it may be considered an option for suitable patients, and would be preferable to forgoing radiotherapy due to the inconvenience of EBRT.
That treatment experience would be the only important determinant of retrospective patient preference in a randomised population was not anticipated when this research began. The only previous preference study of adjuvant radiotherapy following breast-conserving surgery, and indeed most previous preferences research, had been conducted following more homogeneous treatment Hayman, Fairclough, Harris, & Weeks, 1997) . The methodology and timing of administration of Stage 1 of this study was therefore based on these prior validated studies; furthermore, the validity of the paper-based questionnaire methodology had also been established (Blinman et al., 2010) . Our results from Stage 1 of the study are the first to question the validity of eliciting preferences post-treatment and to identify the potential role of avoidance of decisional regret. There was no indication that other aspects of the discrete choice methodology, or the use of a paperbased questionnaire, were less valid in this population than in prior studies. A concurrent study of patient preferences for TARGIT-IORT in the USA reported that 91% of patients found TARGIT-IORT acceptable, with a median increase in acceptable risk of 2.3% (Alvarado et al., 2014) . This is comparable to the "low increased risk" category (a 1%-3% increase) in the present study which was acceptable to 91% of the TARGIT-IORT group, 38% of the TARGIT-EBRT group, 66% of the pre-treatment group and 41% of the post-treatment group. However, in that study, combined results were reported from 21 pre-treatment and 60 post-treatment patients. Results from our larger study question the appropriateness of combining these groups.
Another study investigating preferences for adjuvant chemotherapy (ACT) after early breast cancer showed stability of preferences before and after treatment; however importantly, these F I G U R E 4 Preferred treatment option-Stage-2. EBRT: external beam radiotherapy; IORT: intraoperative radiotherapy; WLE: wide local excision patients had selected their treatment, rather than being randomised (Jansen et al., 2001) .
Our results challenge the utility of eliciting patient preferences post-treatment in a randomised controlled trial. This population does not represent the knowledge base of treatment-naïve patients, and results may be significantly biased by the avoidance of decision regret, albeit an unconscious bias, in patients who have completed treatment. This interpretation is supported by a recent preference study in patients with endometrial cancer who were randomised to receive ACT vs. no ACT. Preferences were elicited both after randomisation but before treatment, and 9 months later (after treatment) (Blinman et al., 2016) . Findings were similar to our study, with patients who had received ACT requiring smaller benefits to accept ACT than those who did not receive it, and less benefit required post-treatment than pre-treatment. These results suggest that the actual experience of ACT treatment may have been better than anticipated, or that preferences justified participation in the randomised trial and avoided decision regret. These results also explain the surprising finding that some women will accept almost zero benefit for ACT for early breast cancer when preferences are elicited after treatment (Duric & Stockler, 2001;  Vaz-Luis et al., 2017).
| CONCLUSION
In terms of the primary goal of this research, we found that women
who had yet to receive radiotherapy for early breast cancer indicated that TARGIT-IORT was an acceptable treatment option, with the majority of patients also willing to accept a higher risk of recurrence in order to have the more convenient treatment option. The most striking finding of this research was however the incidental discovery that preferences elicited post-treatment are significantly biased by the experience of treatment received. Preferences elicited post-treatment appear instead to be an indirect method of eliciting patient satisfaction of treatment already received, and therefore offer a biased account of preference, rather than a consumer perspective of all potential treatments on offer. The results of our study strongly challenge the use and interpretation (and thus the validity) of post-treatment preference studies. We recommend that both qualitative (Duric, Fallowfield, et al., 2005; Jansen et al., 2001 ) and quantitative pre-treatment patient preference studies are utilised in future research, together with post-treatment preferences and measurements of treatment satisfaction and/or decision regret.
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